Corporate GovernanceMay 28, 2026, 04:21 PM
Karyopharm Stockholders Approve 3M Share Equity Plan Increase; Grants PSUs
AI Summary
Karyopharm Therapeutics Inc. stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing available shares by 3,000,000. The Board also approved a broad-based retention program, granting 3,838,380 performance-based restricted stock units (PSUs) to eligible employees, including named executive officers and the CEO. Additionally, stockholders elected two Class I directors and approved an amendment to the 2013 Employee Stock Purchase Plan, increasing shares by 1,400,000.
Key Highlights
- Stockholders approved increasing shares for the 2022 Equity Incentive Plan by 3,000,000.
- Board approved a further 950,000 share increase for the 2022 Plan, subject to future stockholder approval.
- 3,838,380 performance-based restricted stock units (PSUs) granted under a broad-based retention program.
- CEO Richard Paulson received 343,000 PSUs for each of two awards, totaling 686,000 PSUs.
- Stockholders elected Barry E. Greene and Christy J. Oliger as Class I directors.
- Stockholders approved increasing shares for the 2013 Employee Stock Purchase Plan by 1,400,000.
Price Impact
More from KPTI